|Bid||111.55 x 1300|
|Ask||112.47 x 1300|
|Day's Range||111.01 - 112.25|
|52 Week Range||84.64 - 132.13|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||18.15|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||2.58 (2.23%)|
|1y Target Est||124.71|
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Eli Lilly announced positive results in a long-term trial of its diabetes drug Trulicity, but that doesn’t seem to have been enough for Wall Street.
Lilly (LLY) presents additional data from studies on investigational diabetes products ultra-rapid-acting lispro and tirzepatide and outcomes study (REWIND) on Trulicity at ADA.
"I bet this market can go higher still as long as the President works out something with Mexico over the weekend," Jim Cramer says.
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Eli Lilly and Co's migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks, the Food and Drug Administration said https://reut.rs/2QMtzVE. Emgality belongs to a new class of drugs called CGRP inhibitors that are used to prevent migraines or reduce their frequency. It competes with Ajovy from Teva Pharmaceutical Industries Ltd and Amgen Inc's Aimovig, all approved within months of each other last year, creating a fierce battle for market share.
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance. Novartis's Kisqali had $235 million in sales in 2018, well behind the $4.1 billion for Ibrance, as Pfizer's first-to-market drug captured the lion's share of women with metastatic HR+/HER2- cancer.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.